Showing results (441-450 of 451) with videos related to
Sort By:
Pageof 46
Lancet (London, England)|June 10, 2021
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialYu-Pei Chen, Xu Liu, Qin Zhou, et al.Nature Cancer|July 1, 2026
Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 studyYa-Lan Tao, Dong-Hong Wu, Qin Zhou, et al.Cancer Communications (London, England)|October 26, 2021
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinomaLing-Long Tang, Yu-Pei Chen, Chuan-Ben Chen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III TrialYuan Zhang, Lei Chen, Guo-Qing Hu, et al.Nature|March 12, 2026
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinomaJiawei Lv, Dan-Xue Zheng, Jin-Hui Liang, et al.The New England Journal of Medicine|June 1, 2019
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal CarcinomaYuan Zhang, Lei Chen, Guo-Qing Hu, et al.The Lancet. Oncology|September 4, 2025
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlasLing-Long Tang, Cheng-Long Huang, Shao-Jun Lin, et al.The Lancet. Oncology|September 4, 2025
Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlasLing-Long Tang, Cheng-Long Huang, Shao-Jun Lin, et al.Lancet (London, England)|June 2, 2024
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialXu Liu, Yuan Zhang, Kun-Yu Yang, et al.JAMA|March 13, 2025
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical TrialYe-Lin Liang, Xu Liu, Liang-Fang Shen, et al.Pageof 46